Tatiana Prowell on the Regulatory Perspectives on CNS Disease in Clinical Trials
Jarushka Naidoo, Full Professor and Consultant Medical Oncologist at Royal College of Surgeons in Irelan, shared a post on X:
“Superb talk by Tatiana Prowell on the Regulatory Perspectives on including patients with CNS disease in clinical trials.
Insights on:
– articulating the case to sponsors
– de-risking trials
– alectinib in ALK+ NSCLC as test case.”
Amir Safavi, Head and Neck Radiation Oncologist of the Department of Radiation Oncology at the University of Toronto, shared this post, adding:
“From Radiation Oncology perspective, crucial that future trials document RT treatment history well (both at baseline & off protocol use) to make sure added CNS efficacy of drugs well understood (see NEJM LTE by Sahgal Arjun et al re: Adagrasib)”
More posts featuring Tatiana Prowell on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023